Simurosertib
Simurosertib, also known as TAK-931, is an orally bioavailable inhibitor of cell division cycle 7 (cell division cycle 7-related protein kinase; CDC7), with potential antineoplastic activity. Upon administration, TAK-931 binds to and inhibits CDC7; this prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis. This inhibits cell growth in CDC7-overexpressing tumor cells. CDC7, a serine/threonine kinase and cell division cycle protein, is overexpressed in a variety of cancers and plays a key role in the activation of DNA replication and the regulation of cell cycle progression
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Simurosertib |
|---|---|
| Iupac 化学名称 | Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)- |
| 同义词 | TAK-931; TAK 931; TAK931; Simurosertib. |
| 英文同义词 | TAK-931; TAK 931; TAK931; Simurosertib. |
| 分子式 | C17H19N5OS |
| 分子量 | 341.433 |
| Smile | O=C1C2=C(C=C(C3=CNN=C3C)S2)N=C([C@H]4N(CC5)CCC5C4)N1 |
| InChiKey | XGVXKJKTISMIOW-ZDUSSCGKSA-N |
| InChi | InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)/t13-/m0/s1 |
| Cas号 | 1330782-76-7 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 固体粉末 |
|---|---|
| 纯度 | 98% Min. |
| 存储 | 干燥、黑暗，短期（日至周）0-4摄氏度，长期（月至年）0-20摄氏度。 |
| 可溶性 | 可溶于DMSO |
| 处理方式 | |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周。 |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Kurasawa O, Miyazaki T, Homma M, Oguro Y, Imada T, Uchiyama N, Iwai K,
Yamamoto Y, Ohori M, Hara H, Sugimoto H, Iwata K, Skene R, Hoffman ID, Ohashi A,
Nomura T, Cho N. Discovery of a Novel, Highly Potent, and Selective
Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety
(TAK-931) as an Orally Active Investigational Anti-Tumor Agent. J Med Chem. 2020
Jan 2. doi: 10.1021/acs.jmedchem.9b01427. [Epub ahead of print] PubMed PMID:
31895562.
2: Gad SA, Ali HEA, Gaballa R, Abdelsalam RM, Zerfaoui M, Ali HI, Salama SH,
Kenawy SA, Kandil E, Abd Elmageed ZY. Targeting CDC7 sensitizes resistance
melanoma cells to BRAF(V600E)-specific inhibitor by blocking the CDC7/MCM2-7
pathway. Sci Rep. 2019 Oct 2;9(1):14197. doi: 10.1038/s41598-019-50732-w. PubMed
PMID: 31578454; PubMed Central PMCID: PMC6775054.
3: Iwai K, Nambu T, Dairiki R, Ohori M, Yu J, Burke K, Gotou M, Yamamoto Y, Ebara
S, Shibata S, Hibino R, Nishizawa S, Miyazaki T, Homma M, Oguro Y, Imada T, Cho
N, Uchiyama N, Kogame A, Takeuchi T, Kurasawa O, Yamanaka K, Niu H, Ohashi A.
Molecular mechanism and potential target indication of TAK-931, a novel
CDC7-selective inhibitor. Sci Adv. 2019 May 22;5(5):eaav3660. doi:
10.1126/sciadv.aav3660. eCollection 2019 May. PubMed PMID: 31131319; PubMed
Central PMCID: PMC6531005.
